Clinical Trials
2 trialsNCT06151847 2026-04-30
Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma
University of Kansas Medical Center
Phase 2 Completed
NCT02360579 2026-03-25
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Completed